

Zidovudine with lamivudine

The properties listed below are those particular to the combination only. For the properties of the components please consider, zidovudine p. 438, lamivudine p. 436.

● INDICATIONS AND DOSE

HIV infection in combination with other antiretroviral drugs

► BY MOUTH

- Child (body-weight 14–20 kg): 0.5 tablet twice daily
- Child (body-weight 21–29 kg): 0.5 tablet daily, to be given in the morning and 1 tablet daily, to be given in the evening
- Child (body-weight 30 kg and above): 1 tablet twice daily

● **INTERACTIONS** → Appendix 1: lamivudine · zidovudine

● **RENAL IMPAIRMENT** Avoid if estimated glomerular filtration rate less than 50 mL/minute/1.73 m².

● DIRECTIONS FOR ADMINISTRATION

COMBIVIR® TABLETS Tablets may be crushed and mixed with semi-solid food or liquid just before administration.

● **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Tablet

► Zidovudine with lamivudine (Non-proprietary)

Lamivudine 150 mg, Zidovudine 300 mg Zidovudine 300mg / Lamivudine 150mg tablets | 60 tablet [PoM] £240.10-£255.10

► Combivir (ViiV Healthcare UK Ltd)

Lamivudine 150 mg, Zidovudine 300 mg Combivir 150mg/300mg tablets | 60 tablet [PoM] £300.12

ANTIVIRALS > PROTEASE INHIBITORS, HIV

Protease inhibitors

● **CONTRA-INDICATIONS** Acute porphyrias p. 624

● **CAUTIONS** Haemophilia (increased risk of bleeding)

● SIDE-EFFECTS

- **Common or very common** Alopecia · anaemia · angioedema · anxiety · appetite abnormal · arthralgia · asthenia · diabetes mellitus · diarrhoea · dizziness · dry mouth · dyslipidaemia · dyspnoea · fever · gastrointestinal discomfort · gastrointestinal disorders · headache · hepatic disorders · hypersensitivity · hypertension · malaise · muscle complaints · nausea · neutropenia · oral ulceration · pancreatitis · peripheral neuropathy · seizure · skin reactions · sleep disorders · taste altered · vomiting
- **Uncommon** Drowsiness · immune reconstitution inflammatory syndrome · osteonecrosis · Stevens-Johnson syndrome · weight increased

● **HEPATIC IMPAIRMENT** In general, manufacturers advise use with caution in patients with chronic hepatitis B or C (increased risk of hepatic side-effects).

Atazanavir

11-Sep-2018

● INDICATIONS AND DOSE

HIV infection in combination with other antiretroviral drugs—with low-dose ritonavir

► BY MOUTH

- Child 6–17 years (body-weight 15–19 kg): 150 mg once daily
- Child 6–17 years (body-weight 20–39 kg): 200 mg once daily
- Child 6–17 years (body-weight 40 kg and above): 300 mg once daily

● **CAUTIONS** Cardiac conduction disorders · electrolyte disturbances · predisposition to QT interval prolongation

● **INTERACTIONS** → Appendix 1: HIV-protease inhibitors

● SIDE-EFFECTS

- **Uncommon** Chest pain · depression · disorientation · drug reaction with eosinophilia and systemic symptoms (DRESS) · gallbladder disorders · gynaecomastia · haematuria · memory loss · myopathy · nephritis tubulointerstitial · nephrolithiasis · proteinuria · syncope · torsade de pointes · urinary frequency increased
- **Rare or very rare** Gait abnormal · oedema · palpitations · QT interval prolongation · renal pain · vasodilation

SIDE-EFFECTS, FURTHER INFORMATION Mild to moderate rash occurs commonly, usually within the first 3 weeks of therapy. Severe rash occurs less frequently and may be accompanied by systemic symptoms. Discontinue if severe rash develops.

● **PREGNANCY** Theoretical risk of hyperbilirubinaemia in neonate if used at term.

Monitoring In pregnancy, monitor viral load and plasma-atazanavir concentration during third trimester.

● **HEPATIC IMPAIRMENT** Manufacturer advises caution in mild impairment; avoid in moderate to severe impairment (no information available).

● **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Capsule

CAUTIONARY AND ADVISORY LABELS 5, 21

► Reyataz (Bristol-Myers Squibb Pharmaceuticals Ltd)

Atazanavir (as Atazanavir sulfate) 150 mg Reyataz 150mg capsules | 60 capsule [PoM] £303.38 (Hospital only)

Atazanavir (as Atazanavir sulfate) 200 mg Reyataz 200mg capsules | 60 capsule [PoM] £303.38 (Hospital only)

Atazanavir (as Atazanavir sulfate) 300 mg Reyataz 300mg capsules | 30 capsule [PoM] £303.38 (Hospital only)

Darunavir

31-Jul-2018

● INDICATIONS AND DOSE

HIV infection in combination with other antiretroviral drugs in patients previously treated with antiretroviral therapy—with low-dose ritonavir

► BY MOUTH

- Child 3–17 years (body-weight 15–29 kg): 375 mg twice daily
- Child 3–17 years (body-weight 30–39 kg): 450 mg twice daily
- Child 3–17 years (body-weight 40 kg and above): 600 mg twice daily
- Child 12–17 years: 800 mg once daily, once daily dose only to be used if no resistance to darunavir, if plasma HIV-RNA concentration less than 100 000 copies/mL, and if CD4 cell count greater than 100 cells × 10⁶/litre

HIV infection in combination with other antiretroviral drugs in patients not previously treated with antiretroviral therapy—with low-dose ritonavir

► BY MOUTH

- Child 12–17 years (body-weight 40 kg and above): 800 mg once daily

● **INTERACTIONS** → Appendix 1: HIV-protease inhibitors

● SIDE-EFFECTS

- **Uncommon** Angina pectoris · arrhythmias · burping · chest pain · concentration impaired · confusion · constipation · cough · depression · dry eye · eye erythema · feeling hot · flushing · gout · gynaecomastia · haemorrhage · herpes simplex · hyperglycaemia · hypothyroidism · leucopenia · memory loss · mood altered · muscle weakness · myocardial infarction · nail discoloration · nephrolithiasis · oral disorders · osteoporosis · pain · peripheral oedema · polydipsia · QT interval prolongation · renal impairment · sensation abnormal · sexual dysfunction · sweat changes ·